Flexion Therapeutics (FLXN) PT Lowered to $16 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts FLXN Hot Sheet
Price: $24.11 +0.88%
Rating Summary:
11 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
11 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Oppenheimer analyst Francois Brisebois lowered the price target on Flexion Therapeutics (NASDAQ: FLXN) to $16.00 (from $19.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK304 at Goldman Sachs
- Insulet Corporation (PODD) PT Raised to $200 at Jefferies
- Avis Budget Group (CAR) PT Lowered to $125 at Susquehanna
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
